Ingrezza

News

Neurocrine achieves a first with tardive dyskinesia drug Ing...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD.

News

PMV cues up filing for first p53-directed cancer therapy

PMV is preparing to file for approval of its first-in-class oral p53 protein reactivator, rezatopopt, for ovarian cancer in the first quarter of 2027.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks